Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

No phase data available

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT03964480Recruiting

Prospective Observational International Registry of Patients With Newly Diagnosed Peripheral T Cell Lymphoma.

Role: lead

NCT04587388Recruiting

Towards Personalized Medicine for Refractory/Relapsed Follicular Lymphoma Patients: the Cantera/Lupiae Registry

Role: collaborator

NCT01250223Completed

Study of Prognosis of Follicular Lymphoma Through a Prospective Collection of Data (F2-study)

Role: lead

NCT01142674Completed

T-Cell Project: Prospective Collection of Data in Patients With Peripheral T-Cell Lymphoma

Role: lead

All 4 trials loaded